The mTORC2‐Akt1 Cascade Is Crucial for c‐Myc to Promote Hepatocarcinogenesis in Mice and Humans
Zhong Xu,Meng Xu,Pin Liu,Shu Zhang,Runze Shang,Yu Qiao,Li Che,Silvia Ribback,Antonio Cigliano,Katja Evert,Rosa M. Pascale,Frank Dombrowski,Matthias Evert,Xi Chen,Diego F. Calvisi,Xin Chen
DOI: https://doi.org/10.1002/hep.30697
IF: 17.298
2019-06-21
Hepatology
Abstract:<p>Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with limited treatment options. The c‐Myc transcription factor is a pivotal player in hepatocarcinogenesis, but the mechanisms underlying c‐Myc oncogenic activity in the liver remain poorly delineated. Mammalian target of Rapamycin complex 2 (mTORC2) has been implicated in cancer by regulating multiple AGC kinases, especially AKT proteins. In the liver, AKT1 and AKT2 are widely expressed. While AKT2 is the major isoform downstream of activated PI3K and loss of Pten‐induced HCC, the precise function of AKT1 in hepatocarcinogenesis is largely unknown. In the present study, we demonstrate that mTORC2 is activated in c‐Myc‐driven mouse HCC, leading to phosphorylation/activation of Akt1, but not Akt2. Ablation of <i>Rictor</i> inhibited c‐Myc induced HCC formation <i>in vivo</i>. Mechanistically, we discovered that loss of <i>Akt1</i>, but not <i>Akt2</i>, completely prevented c‐Myc HCC formation in mice. Silencing of Rictor or Akt1 in c‐Myc HCC cell lines inhibited p‐Foxo1 expression and strongly suppressed cell growth <i>in vitro</i>. In human HCC samples, c‐MYC activation is strongly correlated with p‐AKT1 expression. Higher expression of RICTOR and AKT1, but not AKT2, is associated with poor HCC patient survival. In c‐Myc mice, while Rapamycin, an mTORC1 inhibitor, had limited efficacy to prevent c‐Myc‐driven HCC progression, dual mTORC1 and mTORC2 inhibitor MLN0128 effectively promoted tumor regression by inducing apoptosis and necrosis. </p><h3> Conclusion</h3><p>Our study indicates the functional contribution of mTORC2/Akt1 along c‐Myc induced hepatocarcinogenesis. AKT isoforms, AKT1 and AKT2, have distinct roles along HCC development and progression. Targeting both mTORC1 and mTORC2 may be required for effective treatment of human HCC displaying c‐Myc amplification or overexpression.</p>
gastroenterology & hepatology